Phase 3 Oesophageal Cancer Trial, Recruiting NCT06676449 Sponsor: Fudan University Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 3 Oesophageal Cancer Trial, Recruiting

NCT06676449
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are aged between 18 and 75 years old
  • People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of throat/food pipe cancer) confirmed by a tissue sample test
  • People whose cancer has been staged at a certain level based on standard medical staging guidelines, including cases where cancer may have spread to lymph nodes near the collarbone (confirm with trial site for full staging details)
  • People who are generally well enough to carry out daily activities, rated 0 or 1 on a standard medical fitness scale
  • People who are expected to live for at least 3 months
  • People whose blood counts, liver function, and kidney function results are within acceptable ranges as determined by blood tests
  • People who have received no more than 3 cycles of immunotherapy and/or chemotherapy prior to joining
  • People who provide written consent to participate

Who may not be able to join:

  • People who have a hole in their food pipe (esophageal perforation) or who are vomiting blood
  • People who have an active autoimmune disease, or a history of autoimmune conditions such as autoimmune hepatitis, lung inflammation, eye inflammation, bowel inflammation, or certain thyroid conditions (some exceptions may apply — confirm with trial site)
  • People who are allergic to the type of medication used in this trial, including PD-1 inhibitor injections or any of their ingredients
  • People with serious or uncontrolled heart problems, such as significant heart failure, unstable chest pain, a heart attack within the past year, or a serious irregular heartbeat requiring treatment
  • People with HIV or other immune system deficiencies, active hepatitis B or C infection, or active tuberculosis
  • People who have had an active infection or an unexplained high fever (above 38.5°C) within the two weeks before joining the trial (unless the fever is believed to be caused by the cancer itself)
  • People who are pregnant, breastfeeding, or who are unwilling to use contraception during the trial
  • People with other serious conditions, including significant mental illness, or other circumstances that the trial doctor believes could affect safety or the collection of trial data

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +862164175590

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 November 2024
Est. completion
31 October 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PFS for patients with TDLN V15 ≤ 50%; PFS for all patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov